Ab	antibody
ABC	antibodies bound per cell
ADC	antibody–drug conjugate
AML	acute myeloid leukemia
BPDCN	blastic plasmacytoid dendritic cell neoplasm
CAR-T	chimeric antigen receptor T cell
cHL	classical Hodgkin lymphoma
DAR	drug-to-antibody ratio
DLBCL	diffuse large B-cell lymphoma
EC50	half-maximal effective concentration
FACS	fluorescence-activated cell sorting
FCS	fetal calf serum
hCD45	human CD45
hIL3RA	human IL3RA
HL	Hodgkin lymphoma
IC50	half-maximal inhibitory concentration
IGN	indolinobenzodiazepine pseudodimer
IL-3	interleukin 3
IL3RA	interleukin 3 receptor subunit alpha
IL3RA-Ab	IL3RA-targeting antibody
i.p.	intraperitoneal(ly)
i.v.	intravenous(ly)
KD	dissociation constant
KSP	kinesin spindle protein
KSPi	kinesin spindle protein inhibitor
MDS	myelodysplastic syndrome
MFI	median fluorescence intensity
MST	median survival time
Papp	apparent permeability
PBD	pyrrolobenzodiazepine
PBS	phosphate-buffered saline
pDCs	plasmacytoid dendritic cells
PDX	patient-derived xenograft
P-gP	P-glycoprotein
Q7D	once weekly
Q14D	every two weeks
Q21D	every three weeks
rrMM	relapsed refractory multiple myeloma
s.c.	subcutaneous(ly)
siRNA	small interfering RNA
SPR	surface plasmon resonance